indazoles has been researched along with Adrenal Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X; Zhong, S | 1 |
| Auchus, RJ; Bible, KC; Burton, JK; Harris, P; Jasim, S; Jimenez, C; Sideras, K; Suman, VJ; Worden, FP | 1 |
1 trial(s) available for indazoles and Adrenal Cancer
| Article | Year |
|---|---|
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease-Free Survival; Electrocardiography; Endocrine Gland Neoplasms; Female; Humans; Indazoles; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Failure | 2017 |
1 other study(ies) available for indazoles and Adrenal Cancer
| Article | Year |
|---|---|
PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; PC12 Cells; Pheochromocytoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2020 |